Leonteq Securities’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$31.2K Sell
1,546
-286
-16% -$7.68K ﹤0.01% 859
2026
Q2
$46.4K Buy
1,832
+293
+19% +$6.45K ﹤0.01% 822
2026
Q1
$34.3K Sell
1,539
-417
-21% -$10K ﹤0.01% 914
2025
Q4
$52.2K Sell
1,956
-1,653
-46% -$39.5K ﹤0.01% 947
2025
Q3
$77K Buy
3,609
+1,257
+53% +$29.7K ﹤0.01% 801
2025
Q2
$50.7K Buy
2,352
+52
+2% +$967 ﹤0.01% 846
2025
Q1
$38.2K Buy
2,300
+444
+24% +$8.07K ﹤0.01% 872
2024
Q4
$34.1K Buy
+1,856
New +$30K ﹤0.01% 895
2021
Q1
– Sell
-6,857
Closed -$367K – 974
2020
Q4
$367K Buy
+6,857
New +$340K 0.02% 460

Other funds holding ACAD

Leonteq Securities's ACAD Position: Q3 2026 in Review

Leonteq Securities reduced its Acadia Pharmaceuticals (ACAD) stake by 16% in Q3 2026, selling an estimated $7.68K and leaving 1,546 shares worth $31.2K. The position accounts for ﹤0.01% of the portfolio, ranked #859.

Leonteq Securities first reported a position in ACAD in Q4 2020 and has held it in 9 quarters since. The position peaked at $367K in Q4 2020. 269 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • Leonteq Securities held 1,546 shares of Acadia Pharmaceuticals worth $31.2K as of Q3 2026.
  • Leonteq Securities sold 286 Acadia Pharmaceuticals shares in Q3 2026, an estimated $7.68K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Leonteq Securities's portfolio in Q3 2026, its #859 holding.
  • Leonteq Securities first reported a position in Acadia Pharmaceuticals in Q4 2020 and has held it in 9 quarters since.
  • Leonteq Securities's Acadia Pharmaceuticals position peaked at $367K in Q4 2020.
  • 269 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Leonteq Securities's 13F filing for Q3 2026, filed 29 Oct 2026.